Non-invasive prenatal diagnosis (NIPD) is based on fetal DNA analysis starting from a simple peripheral blood sample, thus avoiding risks associated with conventional invasive techniques. During pregnancy, the fetal DNA increases to approximately 3-13% of the total circulating free DNA in maternal plasma. The very low amount of circulating cell-free fetal DNA (ccffDNA) in maternal plasma is a crucial issue, and requires specific and optimized techniques for ccffDNA purification from maternal plasma. In addition, highly sensitive detection approaches are required. In recent years, advanced ccffDNA investigation approaches have allowed the application of non-invasive prenatal testing (NIPT) to determine fetal sex, fetal rhesus D (RhD) genotyping, aneuploidies, micro-deletions and the detection of paternally inherited monogenic disorders. Finally, complex and innovative technologies such as digital polymerase chain reaction (dPCR) and next-generation sequencing (NGS) (exhibiting higher sensitivity and/or the capability to read the entire fetal genome from maternal plasma DNA) are expected to allow the detection, in the near future, of maternally inherited mutations that cause genetic diseases. The aim of this review is to introduce the principal ccffDNA characteristics and their applications as the basis of current and novel NIPT.
Introduction
Non-invasive prenatal diagnosis (NIPD) is based on the discovery, in 1997, of circulating cell-free fetal DNA (ccffDNA) within maternal plasma [1] and its aim is to identify genetic abnormalities from the analysis of maternal blood during pregnancy. Currently, first-trimester prenatal diagnosis requires invasive obstetric procedures such as amniocentesis or chorionic villus sampling (CVS), which carry a potential miscarriage risk (with a frequency of approximately 0.5-1%) [2] . The discovery of ccffDNA has facilitated the development of safer and earlier testing procedures based on a simple sampling of maternal blood.
Non-invasive prenatal testing (NIPT) has been applied to the determination of fetal sex [3] , fetal rhesus D (RhD) genotyping [4] , and identification of some pregnancyassociated conditions (such as pre-eclampsia) [5, 6] , aneuploidies [7] , and paternally inherited monogenic disorders [7] [8] [9] . Recently, significant advances have been achieved that would extend the potential applications to fetal whole-genome sequencing and detection of maternally inherited mutations [10] [11] [12] [13] [14] .
Circulating Fetal DNA
In 1997, Lo et al. [1] reported for the first time the presence of fetal DNA in maternal blood, applying a simple and sensitive Y chromosome-specific polymerase chain reaction (PCR) assay to detect circulating fetal DNA from women bearing male fetuses. A year later, Lo et al. [15] demonstrated that the fetal DNA concentration was very similar in maternal plasma and serum, but a larger maternal DNA content was present in serum, causing less efficient detection of fetal DNA. For this reason, maternal plasma is usually preferred as the source of fetal DNA used for diagnosis purposes. Furthermore, using quantitative real-time PCR (qPCR), the same authors determined the concentration of fetal DNA in maternal plasma as 3.4% and 6.2% of total circulating DNA at early and late gestation, respectively [15] .
While different fetal cell types have been found in maternal blood (such as trophoblasts, leukocytes, nucleated red blood cells, and erythrocytes) [16] , a higher amount of ccffDNA is present in maternal plasma as compared with fetal DNA extracted from the cellular component of maternal blood [17] . Therefore, ccffDNA is generally preferred for diagnostic purposes.
Amount and Size of Cell-Free Fetal DNA (ccffDNA)
There is general agreement on the fact that the enrichment of ccffDNA in the blood is caused by (1) apoptosis of fetal hematopoietic cells [18] , (2) transfer of fetal cell-free DNA through the placenta [19] , and (3) trophoblast destruction [20] , with the latter cause being the most important. In fact, the principal origin of fetal nucleic acids in maternal plasma has been reported to be due to trophoblast breakdown, generating apoptotic fragments included in microvesicles [21] , associated with continuous trophoblast turnover. These fetal cells quickly disappear after birth when the placenta is removed. A further cause of the increased fetal DNA concentration is placental expansion and extension of the maternal-fetal interface associated with the progression of the pregnancy [19, 22] .
As reported by Lo et al. [15] , the fetal DNA in maternal plasma reaches a mean of 25.4 and 292.2 genome equivalents/mL in early and late pregnancy, respectively, with the genome equivalent defined as the amount of a DNA sequence present in one diploid cell.
Fetal DNA comprises only a small portion of total cellfree DNA-close to 10-20% in the last weeks of gestation [23] . The fetal DNA detection time spans from 4 to 5 weeks of gestation until delivery [24] .
The proportion of ccffDNA grows by 0.1% every 7 days between the 10th and 21st gestational week; after the 21st week this increase is faster, with a weekly 1% increase [25] . It should be underlined that the amount of circulating fetal DNA depends, in addition to the gestation period and the progression of the pregnancy, on other factors, such as presence of maternal diseases, body weight [26] , aneuploidies [25] , and twin pregnancies [27, 28] . The very low amount of ccffDNA in maternal plasma is of course a critical issue, requiring highly specific and efficient techniques for DNA purification on one hand and DNA sensitive detection on the other.
Another issue affecting diagnostic protocols is that circulating cell-free DNA in the maternal circulation is highly fragmented. With regards to this point, it was found that the 85.5% of fetal DNA is shorter than 0.3 Kb in early pregnancy (13 or 15 weeks of gestation) [28] , constituting the 28.4% of the < 0.3 Kb fraction in maternal plasma. This percentage increases to 68.7% in the third trimester [28] . Chan et al. [29] and Li et al. [30] reported that 99% of fetus-derived DNA is shorter than 313 base pairs (bp), whereas cell-free maternal DNA had a medium length of about 400-500 bp. In any case, even if the length of ccffDNA is only between 150 and 300 bp, the entire fetal genome is still represented [29, 30] .
Stability of ccffDNA
The stability of ccffDNA is a key factor for obtaining optimal DNA extraction, allowing better performance and greatly facilitating diagnostic analyses. While fetal DNA appears to be quite stable in the maternal plasma, it is promptly cleared after giving birth, therefore eliminating the risk of it persisting into the next pregnancy, which would cause confounding effects [31] [32] [33] . Stability of ccffDNA is maintained by taking particular care during purification and handling and using the correct storage procedure, − 80 °C is recommended [34] . Moreover, it has been found that the efficiency of extraction is also affected by the storage temperature of blood before plasma preparation, with 4 °C being suggested as the optimum temperature [35] . In addition, the fetal fraction in maternal plasma can be reduced due to a maternal blood cellular lysis during the time lapse between blood sampling and plasma preparation [34] . To overcome this drawback, treatment of blood samples with formaldehyde has been proposed in order to prevent cell lysis and plasma DNase activity, leading to increased fetal DNA recovery [36] .
Technologies Applied to Prenatal
Diagnosis Based on ccffDNA
Purification and Enrichment Strategies for ccffDNA Extraction
In respect to purification techniques suitable for ccffDNA extraction, several studies have compared different commercially available DNA extraction kits [39, 40] . Two of the most frequently employed purification systems are QIAamp ® Circulating Nucleic Acid Kit (Qiagen, Venlo, The Netherlands) and QIAamp ® DSP Virus Spin Kit (Qiagen) [39, 40] . However, in NIPT, the circulating maternal DNA interferes with the sensitivity and detection of fetal genetic features, and therefore the ccffDNA concentration in maternal plasma reaches a critical limit, requiring enrichment strategies to increase ccffDNA or fetal cells from maternal plasma.
One possibility for the enrichment of the shorter fetal fragments (143 bp fragments for fetal DNA vs. 166 bp fragments for maternal DNA [29] ) has been proposed based on gel size selection. This was applied to increase the sensitivity of paternal allele detection for β-thalassemia mutations [37] . Alternatively, Lun et al. [38] described a method to discriminate maternal and fetal molecules using 179 and 64 bp amplicons obtained with primers for zinc finger protein ZFX and ZFY genes. Size-based enrichment of fetal DNA is not routinely applied to clinical protocols. Therefore, novel enrichment strategies are much needed in order to increase the proportion of ccffDNA in the DNA samples to be analyzed.
The importance of the enrichment step is demonstrated by the finding that the purification of circulating DNA fractions of a lower molecular weight (100-300 bp) after agarose gel electrophoresis (associated with an increase in the fetal DNA fraction) improves the detection of point mutations and other fetal genotyping activity [41] . COLD-PCR (Co-Amplification at Lower Denaturation Temperature PCR) has also been proposed as an enrichment method, selectively amplifying minority alleles within a background of wild-type alleles [42] . Finally, the new frontier for fetal DNA enrichment might be based on the extensively studied mechanisms of epigenetic regulation such as DNA methylation. In this respect, specific differentially methylated regions in maternal/fetal DNA have been identified and used as biomarkers for ccffDNA enrichment and NIPT for aneuploidies [43] , fetal trisomies [44] , and Down syndrome [45] .
Non-invasive Prenatal Diagnosis Based on ccffDNA
To obtain an NIPD, molecular analysis techniques are required in order to detect fetal genetic alterations using ccffDNA. Some of the frequently proposed methods are well-established, such as qPCR and PCR-based approaches (e.g. nested PCR, PAP [pyrophosphorolysis-activated polymerization]). Other experimental strategies that are useful for NIPD include digital PCR (dPCR) and next-generation sequencing (NGS), both of which are able to characterize very low amounts of fetal DNA, the crucial issue in non-invasive testing.
Digital Polymerase Chain Reaction
The dPCR is a very sensitive method for DNA or RNA quantification that does not require a calibration curve. This technique is based on amplification of a single template using limited diluted samples, producing amplicons mainly derived from one template and detectable using different fluorophores [46] . For each analyzed target, the sample reaction is partitioned into individual wells before the amplification step [46] . A PCR reaction is then performed using fluorescent probes (as in qPCR) and the endpoint fluorescence is measured at the end of the amplification, in order to discriminate positive and negative events for each target [47] . In addition, the absolute quantification of the target is calculated using statistical Poisson distribution [47] . In this way, dPCR permits the exponential/analog results, typical in classical PCR, to be converted to linear/digital signals, allowing statistical analysis of the PCR reactions [46] . The precision and reproducibility of this method depend on the high number of partitions of the diluted sample, increasing the sensitivity and accuracy of the technique [48] and allowing its application to different fields of diagnostics, such as the study of the genetic alterations of the fetus [48, 49] , absolute quantification of ccffDNA [50, 51] , analysis of the copy number variations usually found in tumorigenesis processes [52] , gene expression analysis of microRNAs involved in cell cycle, apoptosis, cell differentiation, cancer [53] , and viral load quantification [54] .
Next-Generation Sequencing
NGS, massively parallel sequencing, or deep sequencing are correlated terms indicating high-throughput DNA sequencing technologies capable of analyzing millions or even billions of sequencing reactions at the same time [55] . NGS permits the entire human genome to be sequenced, but also specific regions, such as coding or target genes, amplicons, or RNA.
Different NGS platforms are now available that are based on various technical principles, such as sequencing by synthesis, pyrosequencing, sequencing by ligation, and ion semiconductor sequencing [56] , but with some common characteristics. In particular, all NGS platforms require a library of small fragments obtained by chemical or enzymatic approaches. At the ends of the fragments, adapters are linked and used both for the clonal amplification (to obtain a measurable signal, e.g., fluorescence intensity or pH difference, allowing sequence determination) and for the sequencing reaction. The amplification generates DNA clusters, each originating from a single library fragment and optically read from repeated cycles of nucleotide incorporation. At the end of the sequencing, all generated reads are analyzed by bioinformatic tools and aligned to a known reference genome [55] . Recently, an innovative NGS platform based on single-molecule real-time sequencing (SMRT) has been developed using a more sensitive detection system and is able to sequence single DNA molecules without the clonal pre-amplification step, which can introduce errors during the amplification reaction [57] .
NGS still has some limits in its application in NIPD, as sequencing to a depth sufficient to detect the fetal DNA genotype is still quite expensive and time consuming. Nevertheless, it is considered the basis of commercially available NIPT, which is currently offered to detect fetal sex, common chromosomal aneuploidies, and small insertions and deletions [58] .
Non-invasive Prenatal Testing Applications
Since the discovery of ccffDNA in maternal plasma [1] , NIPT has been applied to different issues of great interest such as fetal gender determination, detection of X-linked disorders, fetal RhD genotyping, detection of aneuploidies, and studies on monogenic disorders (Table 1 ).
Fetal Gender Determination and X-Linked Disorders
The first application of ccffDNA in maternal plasma was aimed at determining the fetal gender. This issue is extremely important when the mother is a carrier of an X-linked disorder, such as Duchenne muscular dystrophy or hemophilia, because pregnancies with male fetuses are primarily at risk. In addition, this issue is of interest for pregnant women who are at risk of conditions associated with ambiguous development of external genitalia (e.g., congenital adrenal hyperplasia), where early maternal treatment with dexamethasone can reduce the degree of virilization of a female fetus [59, 60] . Furthermore, the cffDNA level in maternal plasma, when looking at the copy number of a Y-specific sequence, has been reported as an indicator for pre-eclampsia [61] . In particular, Zhong et al. [61] demonstrated higher ccffDNA levels in plasma samples collected in the second trimester for pregnant women who later developed pre-eclampsia.
Fetal sex is routinely determined by ultrasound scanning in the second trimester or amniocentesis or CVS in the first trimester, but for earlier determination of fetal sex, NIPT can be applied using ccffDNA in maternal plasma and approaches based on qPCR.
The most commonly used technology for detecting male fetus-specific DNA in maternal plasma is qPCR amplifying the single-copy SRY (sex-determining region Y) gene located on the Y chromosome as the target gene [62] , the single-copy sequence DYS14 [63] , and the multicopy DAZ gene [64] .
Devaney et al. [65] reported a systematic review including a PubMed-based meta-analysis (1 January 1997-17 April 2011), which identified 146 publications used to determine the clinical validity of non-invasive prenatal sex determination based on ccffDNA analysis in maternal blood and urine, using PCR or qPCR. Despite the expected variability among the considered studies, the overall sensitivity (95.4%) and specificity (98.6%) of the employed technologies were high, but they were found to be unreliable when the analytical tests were performed using blood isolated before 7 weeks of gestation [65] . This conclusion has been confirmed in other studies [3, 66] .
Another paper by Breveglieri et al. [67] demonstrated that cffDNA, obtained during early gestational time periods and not suitable for detection of the SRY gene target by conventional qPCR, can be identified with high accuracy and reliability by employing surface plasmon resonance (SPR)-based biosensors. In fact, samples obtained from maternal plasma at early gestational age were able to generate a positive SPR signal using a pre-amplification step generating PCR products which were then injected onto SPR biosensor chip flow cells, allowing the identification of fetal sex with a high degree of accuracy after the seventh week of gestation. [103, 104] However, it should be pointed out that identification of a female fetus using NIPD is based on the expectation of null results using Y chromosome-specific sequences and therefore may be the source of false negative results if the amount of male fetal DNA is too low to be detected by qPCR. In addition, this method could lead to false-positive results if male DNA contaminates the sample during extraction from the maternal plasma.
Therefore, other approaches are required to selectively detect female fetal DNA, such as assays based on epigenetic markers. Some genes have been identified that display a differential methylation pattern in maternal blood cells and in fetal placenta [68, 69] , allowing us to distinguish maternal from fetal DNA. For example, the maspin gene (SERPINB5) promoter is unmethylated in the placenta but hypermethylated in maternal blood cells [68, 70] , while the RASSF1A gene (a tumor suppressor gene) is unmethylated in maternal cells and hypermethylated in the placenta [69] .
Another strategy to detect fetal gender has been suggested by Tang et al. [71] , who successfully identified female fetuses from maternal plasma using paternally inherited short tandem repeats (STRs) located on the X chromosome.
Another aspect in NIPD of X-linked disorders is the investigation of the maternal defect in maternal plasma first and then detection of disease status in the male fetus. For example, Tsui et al. [72] analyzed maternal mutations on 12 plasma samples obtained from seven pregnancies carrying hemophilia risk using microfluidic dPCR. In particular, the relative mutation dosage, calculated by detecting the possible over-repression of the mutant or wild-type allele concentrations in heterozygous women carrying male fetuses, allowed correct determination of the fetal genotype in all studied cases [72] .
Fetal Rhesus D Genotyping
The development of a non-invasive method for the determination of fetal RhD status in Rh-negative pregnant women has been demonstrated to be of fundamental importance both to provide prophylaxis (administrating anti-D immunoglobulins) in pregnancies at high risk for this condition, and to avoid risks (such as miscarriage, feto-maternal hemorrhage, and sensitization) caused by conventional sampling methods (amniocentesis and CVS) [73] .
NIPD of fetal RhD genotypes has been accurately performed using techniques based on PCR [4, 74, 75] . However, a small percentage of cases have been identified as false-positive or -negative due to (1) lack of fetal DNA in maternal plasma at early gestation; and (2) low sensitivity of the employed technology in detecting a small quantity of fetal DNA [4] .
It has been demonstrated that the RhD locus has many variants depending on the maternal geographical origin [76] .
At present, in order to reduce the number of false-positive/-negative results, large-scale clinical trials are underway in the European Union that take into consideration racial differences and which are performing fetal RHD screening with high-sensitivity (99.9%) PCR [77] .
Aneuploidies
The diagnosis of fetal structural chromosomal anomalies have routinely been performed by ultrasound scanning or amniocentesis and CVS, but sequencing technologies can be proposed for earlier NIPT.
NIPD has successfully been applied for the detection of the most common aneuploidies, such as identifying pregnancies at risk of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome) [7, 78] .
Currently, commercially available NIPTs are able to identify common chromosomal aneuploidies (trisomies 21, 18, and 13), sex chromosome abnormalities, and triploidy, these are based on a sequencing approach to gathering the ccffDNA genetic information (Table 2) . These approaches are, at present, available from the ninth to tenth week of gestation and have been extended to allow the detection of microdeletions, microduplications, and paternally inherited mutations causing genetic diseases and/or carrier status [87, 88] . Unfortunately, these types of investigations are only considered as screening tests; therefore, positivity should be confirmed using amniocentesis or CVS.
Another advanced technology applied to the analysis and characterization of aneuploidies for the accurate measurement of chromosomal aneuploidy using ccffDNA obtained from maternal plasma is dPCR [10, 89] . For example, Lee et al. [10] applied dPCR to 877 maternal plasma samples for diagnosis of trisomy 21, introducing a cut-off value and size selection method with 99.66% accuracy.
Monogenic Diseases
The development of a simple, quick, and cheap NIPT for monogenic disorders is of great interest due to their high incidence. However, the detection of fetal single point mutations using ccffDNA is extremely difficult because maternal and fetal sequences are very similar; therefore, the diagnosis of monogenic disorders remains limited to the detection of paternally inherited mutations. When the disease is autosomal dominant and the father carries the mutation or this occurs spontaneously de novo during oocyte or sperm formation, it can easily be detected using the same approach employed in fetal sex or RhD status determination based on qPCR [88] . However, in the case of an autosomal recessive disorder, this is significantly harder to diagnose because the maternally inherited portion of the fetal genome and maternal DNA are identical. Therefore, the development of strategies able to compare the mutant and wild-type alleles at a quantitative level is necessary in order to determine whether the fetus has inherited the mutant or normal allele [90] .
It is not surprising that NIPT needs to be highly sensitive, since fetal DNA in maternal plasma is 20% of the total DNA in the third trimester of pregnancy but only ≤ 10% in the first trimester, when prenatal diagnosis is most useful [88] . Despite the fact that many non-invasive approaches have been developed based on PCR technologies, mass spectrometry (MS), and NGS, none of these have been approved and employed in routine clinical practice (Table 3) . This is mainly due to low sensitivity and reproducibility and the expensive and complex instrumentation requiring specialized staff [88] .
Recently, advanced technologies such as dPCR and NGS have allowed clinical implementation of NIPT because of their high sensitivity and ability to reveal the entire fetal genome from maternal plasma DNA. In the future, these methods are also expected to be able to detect maternally inherited mutations [13, 90, 101, 105] .
Conclusions and Future Perspectives
In recent years NIPD has been becoming increasingly important as it allows investigation of the health status of the fetus without risk to the fetus or mother, although its predictive value is expected to be affected by false-positive rates. In fact, in addition to technical problems, different biological factors can induce false-positive results in NIPT, such as fetal or maternal mosaicism, tumors, and maternal duplication events [106] . For example, in order to reduce the rate of false-positives in NIPT applied to fetal chromosome aneuploidies, Strom et al. [106] designed a clinical assay based on massive parallel shotgun sequencing (MPSS), combining automation of all manual processes with bioinformatics and biostatistics tools.
While current commercial NIPT kits can detect the most common aneuploidies and microdeletions, novel molecular strategies able to identify single point mutations causing genetic disorders are much needed, including NIPT for maternally inherited monogenic diseases. In the future, advanced technologies such as dPCR and NGS could also be very useful for allowing the use of NIPT to be translated from laboratory research to clinical practice in the case of autosomal recessive diseases caused by maternal mutated alleles.
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